Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Non-Hodgkin Lymphoma: early-phase trial registry
58 of 107 indexed Non-Hodgkin Lymphoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #120 of 28,707 conditions by registered trial count.
107 US clinical trials · 58 currently recruiting · #120 of 28,707 conditions by registered trial count
Non-Hodgkin Lymphoma: 107 US clinical trials tracked, 58 recruiting.
Non-Hodgkin Lymphoma is the subject of 107 registered US clinical trials on ClinicalTrials.gov, 58 of them currently open to new participants. 6 are in Phase 3-4 (later-stage) and 86 in Phase 1-2 (earlier-stage). The most active sponsor is Baylor College of Medicine, running 7 of these trials.
Enrollment posture brief
Registry condition non-hodgkin-lymphoma
OPEN 58 | RECR 54% | LATE 6 | EARLY 86 | RANK #120 | SPON 7
Volume-matched condition peers
Nearest open-share peer: Bulimia Nervosa (54% recruiting · 24 trials)
Non-Hodgkin Lymphoma lists 58 open slots (54% of 107 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Non-Hodgkin Lymphoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Non-Hodgkin Lymphoma is recruiting above its size-band peers.
58 of 107 indexed trials (54.2%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Non-Hodgkin Lymphoma trials is spread across many organizations.
Baylor College of Medicine accounts for 7 of 107 trials (6.5%). 77 distinct sponsors appear on at least one study for this condition label.
-
Most Non-Hodgkin Lymphoma trials plan to enrol fewer than 100 people.
Median target enrolment is 54 among the 107 trials that report a genuine target (sentinel values excluded). 68 of those (63.6%) plan for fewer than 100 participants.
-
Non-Hodgkin Lymphoma research is mostly interventional.
98 interventional and 9 observational studies make up this index (91.6% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
107 total, page 1 of 3
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
Wake Forest University Health Sciences
NCT06418204
Evaluating the Impact of Social and Genetic Factors on Outcomes in Adolescent and Young Adult Cancer Survivors
ECOG-ACRIN Cancer Research Group
NCT06002828
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
Eli Lilly and Company
NCT06876649
A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies
BeOne Medicines
NCT05006716
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
Genmab
NCT05283720
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
Lyell Immunopharma
NCT07188558
A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma
Grifols Therapeutics
NCT05645107
Pre-malignant States to Hematologic Malignancies in Firefighters
Wake Forest University Health Sciences
NCT06870760
A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
Eli Lilly and Company
NCT06876662
Study of LYL314 in Aggressive Large B-Cell Lymphoma
Lyell Immunopharma
NCT05826535
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
CellCentric
NCT04068597
CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
City of Hope Medical Center
NCT06059391
Phase1/2 Study of IPH6501 in Patients With Relapsed /Refractory B-Cell Non-Hodgkin Lymphoma
Innate Pharma
NCT06088654
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
National Cancer Institute (NCI)
NCT03223610
Auto Stem Cell Transplant for Lymphoma Patients
Masonic Cancer Center, University of Minnesota
NCT03125642
Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU
Miltenyi Biomedicine
NCT06116110
Lifestyle Intervention of Food and Exercise for Lymphoma Survivors
University of Miami
NCT05839210
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
Imugene Limited
NCT03666000
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma
Hoffmann-La Roche
NCT05169515
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
CRISPR Therapeutics
NCT05643742
AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
Carna Biosciences
NCT05602363
Improving Exercise Capacity With a Tailored Physical Activity Intervention
Wake Forest University Health Sciences
NCT05595577
Mozobil for Autologous Hematopoietic Stem Cell Transplantation
Thomas Jefferson University
NCT07188090
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
Newave Pharmaceutical
NCT04771572
Study of SGR-1505 in Mature B-Cell Neoplasms
Schrödinger
NCT05544019
Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas
Baylor College of Medicine
NCT06176690
Chemoradiotherapy With Targeted Immunotherapy in Pediatric Lymphoma
New York Medical College
NCT05253495
Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma
Marker Therapeutics
NCT05798897
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
Caribou Biosciences
NCT04637763
Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R/R B-NHL Patients
University of Colorado, Denver
NCT05098613
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
Baylor College of Medicine
NCT01853631
CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30)
Baylor College of Medicine
NCT02917083
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma
National Cancer Institute (NCI)
NCT04739813
Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases
Fred Hutchinson Cancer Center
NCT06013423
Amping up With PemJAK
Seda S. Tolu
NCT07283822
Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary Malignancy
Bristol-Myers Squibb
NCT06357754
A Study of Carmustine With and Without Ethanol in Subjects With Lymphoma
VIVUS
NCT06915246
SB-4826 in Adult Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphomas
University of California, San Diego
NCT07222631
Epco, Zanu, Ritux for R/R FL or MZL
Reid Merryman, MD
NCT06563596
ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies
Acepodia Biotech
NCT05653271
Isatuximab During Stem Cell Collection and Transplant in Patients With Multiple Myeloma and Lymphoma
Divaya Bhutani
NCT05346809
Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma
C. Babis Andreadis
NCT04545762
PET Imaging Study of 64Cu-GRIP B for Patients Receiving CD19-directed CAR-T Therapy
Michael Randall
NCT06522932
In-Human CXCR4 Imaging of Hematologic and Solid Tumors Using [68Ga]-Pentixafor-PET
Memorial Sloan Kettering Cancer Center
NCT05093335
Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients
M.D. Anderson Cancer Center
NCT05529069
Study of IOMAB-ACT Followed by CAR-T Cell Therapy for Patients Relapsed or Refractory (Diffuse Large B-cell Lymphoma
University of Texas Southwestern Medical Center
NCT06768905
Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL
New York Medical College
NCT02393157
Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas
National Cancer Institute (NCI)
NCT05389423
CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma
Marcela V. Maus, M.D.,Ph.D.
NCT06026319
TmCD19-IL18 in CD19+ Cancers
University of Pennsylvania
NCT05989204
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 67 |
| Phase 2 | 19 |
| Phase 3 | 4 |
| Phase 4 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Non-Hodgkin Lymphoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Non-Hodgkin Lymphoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Non-Hodgkin Lymphoma page
107 registered trials, 58 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 58 Non-Hodgkin Lymphoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Baylor College of Medicine sponsors the most Non-Hodgkin Lymphoma trials on record, review their full trial history before evaluating a specific study. See Baylor College of Medicine's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Non-Hodgkin Lymphoma condition card totals 107 registered trials; most-linked intervention Cyclophosphamide; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.